Compare ARMOUR Residential REIT, Inc. (ARR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Summit Therapeutics Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.73 (market cap $2.07B), while Summit Therapeutics Inc trades at $15.29 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 5.8× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ARR | SMMT | |
|---|---|---|
Market Cap | $2.07B | $12.06B |
Sector | Financials | Health |
52-Week High | $19.12 | $26.98 |
52-Week Low | $14.05 | $12.55 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.74, up 1.18% with neutral technical signals. The REIT shows strong profitability with 97.43% net income margin and attractive valuation at P/E of 3.78 and P/B of 0.91. Recent Q2 2026 earnings beat expectations at $0.72 per share versus $0.69 estimate. The company maintains consistent dividend payments with recent $0.24 distributions. Cash flow trends show operational stability despite significant investing activities.
ARR presents value opportunity with deep discount to book value and high dividend yield, though mixed earnings performance and heavy mortgage-backed securities exposure create volatility risk. Analyst consensus remains cautious with 60% hold rating, reflecting balanced outlook between attractive valuation and sector-specific headwinds.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
